The aim is to investigate and to find a correlation between tramadol addiction misuse among Algerian males and Dental Local Anesthesia success while performing dental care and oral surgeries.

开始日期2023-06-10

申办/合作机构

The University of Algiers

NCT05804630 / Enrolling by invitationN/AIIT

Efficacy and Safety of Articaine and Lidocaine in Extraction of Wisdom Teeth of Upper and Lower Jaws

Local anesthesia drugs and anesthesia technique play an imperative role in dental treatment. The purpose of this study was to compare the efficacy and safety of different dental local anesthetics drugs and brands in clinical use for the extraction of wisdom teeth.

开始日期2023-03-15

申办/合作机构

National Taiwan University Hospital

NCT04166890 / Completed临床4期IIT

Comparison of the Efficacy and Safety of Two Homologous Active Principles for Local Dental Anesthesia: Non-inferiority Trial

In the complexity of the Dental care the third molar surgery is one of the most common procedures, it is indicated for multiple reasons like infections in root canal, prosthetics or even esthetical purposes. This surgery can be safely performed with the help of local anesthetics, due to their quick action, and reversibility to control pain, reducing possible complications during and after the surgeries.
Among the different types of local anesthetics used in dentistry, the articaine bears characteristics that provide some advantages compared to similar anesthetics like Lidocaine, being one of the most used anesthetics worldwide. Different authors have concluded that it is a safe when used in patients at different ages and it is effective as a local anesthetic in the majority of procedures. It is important for dentists to know the differences or similarities of anesthetics in terms of their effects, safety, dosages required in patients undergoing surgical removal of teeth, as well as the mechanism of action and pharmacological properties, in order to take advantage of its benefits and minimize risks.
This study aims to test the efficacy and safety of an anesthetic solution, based on the same active molecule, articaine, manufactured by two different commercial houses, one domestic and one international, in order to gather scientific evidence and to show that they are not different. This will provide scientific results to help in the selection of any of these brands to be used with confidence in the dental practice. This will strengthen the collaboration between the academy and the companies, which would allow them to improve the quality of their products.
Locally there are no studies available comparing the articaine-type anesthetic with epinephrine at the same concentration, manufactured locally by a national company, to a foreign one, which is an important opportunity to expand the knowledge and create scientific reports, about what a local anesthetic is and what it does.
Finally, this study would contribute to the need to guarantee the quality of medicines in Colombia, by means of compliance with the legal provisions contemplated in resolution 1890 of November 2001 and 1400 of August 2001, issued by the Ministry of Health of Colombia : "Requirements to demonstrate the therapeutic effectiveness, through studies of Bioavailability and Bioequivalence of medicines for a special group of them.

开始日期2018-09-04

申办/合作机构

Universidad de Antíoquia

100 项与盐酸阿替卡因/重酒石酸肾上腺素相关的临床结果

登录后查看更多信息

100 项与盐酸阿替卡因/重酒石酸肾上腺素相关的转化医学

登录后查看更多信息

100 项与盐酸阿替卡因/重酒石酸肾上腺素相关的专利（医药）

登录后查看更多信息

项与盐酸阿替卡因/重酒石酸肾上腺素相关的文献（医药）

2023-05-18·Animals : an open access journal from MDPI

Effects of Different Co-Feeding Protocols on the Early Weaning of Flathead Grey Mullet (Mugil cephalus) Larvae.

Article

作者: Robaina, Lidia ; Vallainc, Dario ; Roo, Javier ; Concu, Danilo ; Loi, Barbara ; Quirós-Pozo, Raquel

The sustainable expansion of aquaculture relies on a sufficient supply of eggs and larvae, which are the first step of life cycle management. However, marine fish larval rearing generally depends on live feed production, which needs additional facilities and labor. The flathead grey mullet (Mugil cephalus), a promising species for aquaculture diversification, has a precocious digestive system development, supporting the feasibility of early weaning strategies. For these reasons, this study evaluated survival, growth, proximate and fatty acid composition, and gene expression of Mugil cephalus larvae reared under three different weaning protocols. Three co-feeding treatments, two with different Artemia sp. concentrations (A100 and A50, 2 and 1 Artemia sp. mL^-1 day^-1, respectively) and one with only rotifers administered as live feed along the feeding trial (A0), were assessed from 22 to 36 days post-hatching (dph). The A0 treatment performed better in survival (64.79 ± 7.40%) than the A100 protocol (32.46 ± 12.82%). In contrast, the larvae of the A100 treatment presented significantly higher final length (15.51 ± 0.86 mm) than those of the A0 treatment (12.19 ± 1.45 mm) and higher final weight (41.28 ± 1.48 mg) than those of the A50 and A0 treatments (31.23 ± 3.65 mg and 24.03 ± 7.99 mg, respectively). On the other hand, the expression of digestive enzyme- and somatotropic factor-related genes did not show differences between treatments. The present results support the convenience of treatment A0 in maximizing survival, as rotifers should be maintained until 30-32 dph (until a total larval length of at least 10 mm). However, to improve growth and minimize size dispersion, Artemia sp. addition is recommended from day 26 to day 29 post-hatching (total larval length of 8 to 9 mm).

2021-10-01·Journal of Hazardous Materials1区 · 环境科学与生态学

The synergistic effect of enhanced photocatalytic activity and photothermal effect of oxygen-deficient Ni/reduced graphene oxide nanocomposite for rapid disinfection under near-infrared irradiation

1区 · 环境科学与生态学

Article

作者: Liu, Lu ; Sun, Jingyu ; Wu, Guizhu ; Guo, Donggang ; Chen, Xue ; Zhang, Ze ; Jin, Zhengguo

The rational design of high antibacterial efficiency are urgently needed as the occurrence of drug-resistance issues. Hence, Ni/reduced graphene oxide nanocomposite (Ni/rGO) with different amounts of oxygen vacancies were fabricated for efficient disinfection. The optimized Ni/rGO (A100) exhibited highly effective inactivation efficacy of 99.6% and 99.5% against Escherichia coli and Bacillus subtilis within 8 min near-infrared (NIR) irradiation through the synergistic effects of photothermal therapy and oxidative damage, which were much higher than single treatment. The A100 nanocomposite achieved an extraordinary photothermal conversion efficiency (35.78%) under the 808 nm irradiation for enhanced photothermal hyperthermia, thereby destroying the cell membrane and accelerating the GSH depletion. The radical scavenger experiment confirmed that •O₂^- and •OH play the chief role in photodisinfection reaction. Besides, A100 could exert significant damage on the ATP synthesis. The excellent photothermal performance and photocatalytic activity can be attributed to the appropriate oxygen vacancy density, which improves the absorption of NIR light and facilitates the separation of photogenerated electron-hole pairs. Besides, the higher NiO content of A100 contributed to improving the photocatalytic effect. Our work demonstrated a promising strategy for efficient water pollution purification caused by pathogenic bacteria.

2020-01-01·Nanotheranostics

Effects of molecular weight and structural conformation of multivalent-based elastin-like polypeptides on tumor accumulation and tissue biodistribution

Article

作者: Lee, Young-Jin ; Kim, Sang Kyoon ; Park, Rang-Woon ; Yi, Aena ; Cheon, Sun-Ha ; Seo, Bo-Yeon ; Sarangthem, Vijaya ; Lee, Byung-Heon ; Singh, Thoudam Debraj

In order to improve clinical outcomes for novel drug delivery systems, distinct optimization of size, shape, multifunctionality, and site-specificity are of utmost importance. In this study, we designed various multivalent elastin-like polypeptide (ELP)-based tumor-targeting polymers in which multiple copies of IL-4 receptor (IL-4R)-targeting ligand (AP1 peptide) were periodically incorporated into the ELP polymer backbone to enhance the affinity and avidity towards tumor cells expressing high levels of IL-4R. Several ELPs with different molecular sizes and structures ranging from unimer to micelle-forming polymers were evaluated for their tumor accumulation as well as in vivo bio-distribution patterns. Different percentages of cell binding and uptake were detected corresponding to polymer size, number of targeting peptides, or unimer versus micelle structure. As compared to low molecular weight polypeptides, high molecular weight AP1-ELP showed superior binding activity with faster entry and efficient processing in the IL-4R-dependent endocytic pathway. In addition, in vivo studies revealed that the high molecular weight micelle-forming AP1-ELPs (A86 and A100) displayed better tumor penetration and extensive retention in tumor tissue along with reduced non-specific accumulation in vital organs, when compared to low molecular weight non-micelle forming AP1-ELPs. It is suggested that the superior binding activities shown by A86 and A100 may depend on the multiple presentation of ligands upon transition to a micelle-like structure rather than a larger molecular weight. Thus, this study has significance in elucidating the different patterns underlying unimer and micelle-forming ELP-mediated tumor targeting as well as the in vivo biodistribution.

项与盐酸阿替卡因/重酒石酸肾上腺素相关的新闻（医药）

2024-06-03

·信狐药迅

山东博安生物国内首个 GLP-1度拉糖肽生物类似药提交上市申请|新受理（5.27-6.2）

本周药品注册受理数据，分门别类呈现，一目了然。(5.27-6.2）小编收到有些用户反应，不想收到咱们每周文章的推送提醒，而有些用户又特别需要这个提醒，在小编强烈要求下，我们给力的程序员终于实现了可以关闭提醒的功能，这个绝对全网独一家喔，不想收到提醒的，只要在信狐药迅对话框内回复关键词“拒收文章提醒”，那么就可以不受推送的打扰啦!新药上市申请药品名称企业注册分类受理号度拉糖肽注射液山东博安生物技术股份有限公司3.3CXSS2400054度拉糖肽注射液山东博安生物技术股份有限公司3.3CXSS2400053度拉糖肽注射液山东博安生物技术股份有限公司3.3CXSS2400052度拉糖肽注射液山东博安生物技术股份有限公司3.3CXSS2400051新药临床申请药品名称企业注册分类受理号CS060380片凯思凯迪(上海)医药科技有限公司1CXHL2400553CS060380片凯思凯迪(上海)医药科技有限公司1CXHL2400552CS060380片凯思凯迪(上海)医药科技有限公司1CXHL2400551ABP2111Na片上海爱博医药科技有限公司1CXHL2400547ABP2111Na片上海爱博医药科技有限公司1CXHL2400546BGB-45035片百济神州(苏州)生物科技有限公司1CXHL2400550BGB-45035片百济神州(苏州)生物科技有限公司1CXHL2400548177Lu-LNC1011注射液烟台蓝纳成生物技术有限公司1CXHL2400545BN104片烨辉医药科技(上海)有限公司1CXHL2400536BN104片烨辉医药科技(上海)有限公司1CXHL2400535HX301胶囊杭州翰思生物医药有限公司1CXHL2400534BGB-24714胶囊百济神州(苏州)生物科技有限公司1CXHL2400533BGB-24714胶囊百济神州(苏州)生物科技有限公司1CXHL2400532BGB-24714胶囊百济神州(苏州)生物科技有限公司1CXHL2400531TQB3702片正大天晴药业集团股份有限公司1CXHL2400530HSK44459片四川海思科制药有限公司1CXHL2400529HSK44459片四川海思科制药有限公司1CXHL2400528HRS-1167片江苏恒瑞医药股份有限公司1CXHL2400544HRS-1167片江苏恒瑞医药股份有限公司1CXHL2400543HRS-1167片江苏恒瑞医药股份有限公司1CXHL2400542SHR2554片江苏恒瑞医药股份有限公司1CXHL2400541SHR7280片江苏恒瑞医药股份有限公司1CXHL2400540SHR7280片江苏恒瑞医药股份有限公司1CXHL2400539HRS-5041片江苏恒瑞医药股份有限公司1CXHL2400538HRS-5041片江苏恒瑞医药股份有限公司1CXHL2400537BCM878口崩片上海云晟研新生物科技有限公司2.2CXHL2400549糠酸莫米松鼻喷雾剂四川普锐特药业有限公司4CYHL2400102重组带状疱疹疫苗(CHO细胞)江苏中慧元通生物科技股份有限公司1.2CXSL2400350SHR-2106注射液广东恒瑞医药有限公司1CXSL2400359注射用HS-20093上海翰森生物医药科技有限公司1CXSL2400358注射用HS-20093上海翰森生物医药科技有限公司1CXSL2400357HS-20117注射液上海翰森生物医药科技有限公司1CXSL2400356XMVA09注射液合肥星眸生物科技有限公司1CXSL2400355夫那奇珠单抗注射液苏州盛迪亚生物医药有限公司1CXSL2400363夫那奇珠单抗注射液苏州盛迪亚生物医药有限公司1CXSL2400362夫那奇珠单抗注射液苏州盛迪亚生物医药有限公司1CXSL2400361注射用LNF2007双特异性抗体山东新时代药业有限公司1CXSL2400360人脐带间充质干细胞注射液浙江泉生生物科技有限公司1CXSL2400353MG-K10人源化单抗注射液上海麦济生物技术有限公司1CXSL2400354SGC001注射液北京舜景生物医药技术有限公司1CXSL2400352注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2400351仿制药申请药品名称企业注册分类受理号依帕司他片中美华世通生物医药科技(武汉)股份有限公司3CYHS2401651氯化钾颗粒山东普瑞曼药业有限公司3CYHS2401648维生素B6注射液北京远方通达医药技术有限公司3CYHS2401646布美他尼注射液北京民康百草医药科技有限公司3CYHS2401641布美他尼注射液北京民康百草医药科技有限公司3CYHS2401640氨磺必利口服溶液常州四药制药有限公司3CYHS2401638氯化钙注射液河北千康医药科技有限责任公司3CYHS2401634异烟肼注射液漯河市汇创医药有限公司3CYHS2401633维生素K1注射液合肥亿帆生物制药有限公司3CYHS2401632维生素K1注射液合肥亿帆生物制药有限公司3CYHS2401631硫辛酸片苏州富士莱医药股份有限公司3CYHS2401626硫辛酸片苏州富士莱医药股份有限公司3CYHS2401625阿替卡因肾上腺素注射液扬州中宝药业股份有限公司3CYHS2401623利伐沙班颗粒南京海纳制药有限公司3CYHS2401606马来酸氯苯那敏注射液宝利化(南京)制药有限公司3CYHS2401605盐酸曲唑酮片重庆圣华曦药业股份有限公司3CYHS2401603复方匹可硫酸钠口服溶液南京海纳制药有限公司3CYHS2401595布洛芬片珠海润都制药股份有限公司3CYHS2401594氯化钾注射液福州基石医药科技有限公司3CYHS2401593多索茶碱糖浆山东朗诺制药有限公司3CYHS2401592重酒石酸去甲肾上腺素注射液锦州奥鸿药业有限责任公司3CYHS2401584吡格列酮二甲双胍片成都倍特药业股份有限公司3CYHS2401579布立西坦口服溶液海南全星制药有限公司3CYHS2401578恩格列净片云鹏医药集团有限公司4CYHS2401650聚乙烯醇滴眼液浙江百代医药科技有限公司4CYHS2401649盐酸尼卡地平注射液河南群益医药科技开发有限公司4CYHS2401647二甲硅油乳剂浙江赛默制药有限公司4CYHS2401645二甲硅油乳剂浙江赛默制药有限公司4CYHS2401644二甲硅油乳剂浙江赛默制药有限公司4CYHS2401643吗啉硝唑氯化钠注射液浙江百代医药科技有限公司4CYHS2401642双氯芬酸二乙胺乳胶剂浙江百代医药科技有限公司4CYHS2401639硫酸氨基葡萄糖胶囊山西复盛公大药厂有限公司4CYHS2401637妥布霉素滴眼液广州仁恒医药科技股份有限公司4CYHS2401636地诺孕素片常州四药制药有限公司4CYHS2401635阿普米司特片天津市中央药业有限公司4CYHS2401630阿普米司特片天津市中央药业有限公司4CYHS2401629阿普米司特片天津市中央药业有限公司4CYHS2401628夫西地酸乳膏浙江百代医药科技有限公司4CYHS2401627恩扎卢胺软胶囊嘉亨(珠海横琴)医药科技有限公司4CYHS2401624塞来昔布胶囊大桐制药(中国)有限责任公司4CYHS2401622盐酸伊立替康脂质体注射液上海研诺医药科技有限公司4CYHS2401621乳果糖口服溶液江苏万高药业股份有限公司4CYHS2401620乳果糖口服溶液江苏万高药业股份有限公司4CYHS2401619美阿沙坦钾片江苏和晨药业有限公司4CYHS2401618美阿沙坦钾片江苏和晨药业有限公司4CYHS2401617碘佛醇注射液重庆药友制药有限责任公司4CYHS2401616碘佛醇注射液重庆药友制药有限责任公司4CYHS2401615乳果糖口服溶液重庆和平制药有限公司4CYHS2401614乳果糖口服溶液重庆和平制药有限公司4CYHS2401613乳果糖口服溶液重庆和平制药有限公司4CYHS2401612利丙双卡因乳膏华熙生物科技股份有限公司4CYHS2401611氟比洛芬凝胶贴膏湖南普道医药技术有限公司4CYHS2401610通滞苏润江片新疆维吾尔药业有限责任公司4CYZS2400001罗沙司他胶囊郑州德迈药业有限公司4CYHS2401609罗沙司他胶囊郑州德迈药业有限公司4CYHS2401608ω-3脂肪酸乙酯90软胶囊北京双鹭药业股份有限公司4CYHS2401607双氯芬酸钠肠溶片浙江京新药业股份有限公司4CYHS2401604盐酸美金刚片云鹏医药集团有限公司4CYHS2401602盐酸米诺环素胶囊珠海同源药业有限公司4CYHS2401601盐酸米诺环素胶囊珠海同源药业有限公司4CYHS2401600他克莫司软膏齐鲁制药(海南)有限公司4CYHS2401599克立硼罗软膏湖北恒安芙林药业股份有限公司4CYHS2401596吡仑帕奈口服混悬液山东朗诺制药有限公司4CYHS2401591盐酸伐昔洛韦片以岭万洲国际制药有限公司4CYHS2401590枸橼酸托法替布缓释片华润双鹤利民药业(济南)有限公司4CYHS2401589艾拉莫德片四川国为制药有限公司4CYHS2401588尼莫地平片哈尔滨三联药业股份有限公司4CYHS2401587西甲硅油乳剂成都诺和晟鸿生物制药有限公司4CYHS2401586盐酸贝尼地平片福建海西新药创制股份有限公司4CYHS2401585磷酸西格列汀片济南高华制药有限公司4CYHS2401583磷酸西格列汀片济南高华制药有限公司4CYHS2401582注射用阿糖胞苷石家庄迪斯凯威医药科技有限公司4CYHS2401581乳果糖口服溶液成都克莱蒙医药科技有限公司4CYHS2401598乳果糖口服溶液成都克莱蒙医药科技有限公司4CYHS2401597吸入用异丙托溴铵溶液广州大光制药有限公司4CYHS2401580拉坦前列素滴眼液广州仁恒医药科技股份有限公司4CYHS2401577盐酸艾司洛尔氯化钠注射液北京新美泰克医药科技有限公司4CYHS2401576盐酸艾司洛尔氯化钠注射液北京新美泰克医药科技有限公司4CYHS2401575进口申请药品名称企业注册分类受理号左甲状腺素钠片Aristo Pharma GmbH5.2JYHS2400033盐酸万古霉素胶囊Orient Pharma Co.,LTD5.2JYHS2400032盐酸万古霉素胶囊Orient Pharma Co.,LTD5.2JYHS2400031地诺孕素片Laboratoires Besins International5.2JYHS2400030Orforglipron胶囊Eli Lilly and Company1JXHL2400123Orforglipron胶囊Eli Lilly and Company1JXHL2400122Orforglipron胶囊Eli Lilly and Company1JXHL2400121Orforglipron胶囊Eli Lilly and Company1JXHL2400120Orforglipron胶囊Eli Lilly and Company1JXHL2400119Orforglipron胶囊Eli Lilly and Company1JXHL2400118克拉屈滨胶囊Merck Healthcare KGaA2.2JXHL2400125克拉屈滨胶囊Merck Healthcare KGaA2.2JXHL2400124盐酸非苏拉生片Daewoong Pharmaceutical Co., Ltd.2.4JXHL2400117呼吸道合胞病毒疫苗Pfizer Inc.3.1JXSL2400107VAY736注射液Novartis Pharma AG1JXSL2400105Dostarlimab注射液GlaxoSmithKline Research & Development Limited2.2JXSL2400106贝利尤单抗注射液GlaxoSmithKline (Ireland) Limited2.2JXSL2400104中药相关申请药品名称企业注册分类受理号参蒲盆安颗粒江苏康缘药业股份有限公司1.1CXZS2400017开心散山东润中药业有限公司3.1CXZS2400019玉女煎颗粒江苏康缘药业股份有限公司3.1CXZS2400018不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

生物类似药

2024-05-01

·药明康德

100%缓解率，精准抗癌疗法2期临床结果积极；克服吃药困难，FDA批准亨廷顿病疗法新剂型

▎药明康德内容团队编辑CDK9抑制剂在特定急性髓系白血病患者中达到100%总缓解率SELLAS Life Sciences公司今日宣布，在研高度选择性CDK9抑制剂SLS009在2a期临床试验中获得积极初步结果。在携带ASXL1突变的复发/难治性急性髓系白血病（r/r AML）患者中，接受优化剂量SLS009治疗的群体达到100%的缓解率。ASXL1突变与所有髓系疾病的不良预后相关，它导致患者对现有治疗方案的应答减弱。新闻稿表示，这一数据支持该公司与美国FDA接洽，讨论在这一患者群体中使用加速批准通道加快SLS009的开发和审评。这项2a期临床试验旨在评估SLS009治疗r/r AML患者的疗效和安全性。截至2024年4月19日，接受优化剂量SLS009治疗的患者群体总缓解率为57%。其中4名携带ASXL1截短突变的患者均获得缓解并且仍然活着。对此前1期临床试验中一名完全缓解时间超过8个月患者的基因突变分析显示，这名患者同样携带ASXL1突变。该公司计划扩展这一2期临床试验的患者队列，招募更多携带ASXL1突变的AML患者，以及携带ASXL1突变之外的骨髓增生异常相关变异的AML患者。FDA批准亨廷顿病疗法新服药方式Neurocrine Biosciences日前宣布，美国FDA批准了其亨廷顿病疗法Ingrezza（valbenazine）的新剂型。这一新剂型给吞咽药片困难的亨廷顿病患者提供了一种替代服药方式。这种名为Ingrezza Sprinkle的新剂型是一种口服颗粒，可以撒在患者吃的软食物上，与食物一起服用。Ingrezza Sprinkle的剂量和生物利用度与已经获批的Ingrezza相同。Ingrezza是一款选择性囊泡单胺转运蛋白2（VMAT2）抑制剂，已经获得FDA的批准治疗与亨廷顿病相关的迟发性运动障碍。在亨廷顿病患者中，与疾病相关的不自主运动可能让吞咽药片变得困难。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level. Retrieved May 1, 2024, from https://www.globenewswire.com/news-release/2024/05/01/2873258/0/en/SELLAS-Announces-Positive-Phase-2-Preliminary-Data-of-SLS009-in-r-r-AML-Achieving-a-100-Response-Rate-in-Patients-with-ASXL1-Mutation-At-the-Optimal-Dose-Level.html[2] Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules. Retrieved May 1, 2024, from https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-us-fda-approval-ingrezzar免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床2期加速审批

2024-03-12

·蒲公英Ouryao

参比制剂目录（第78批）正式发布！

转自：国家药监局编辑：wangxinglai20042024年03月12日，国家药监局发布了第78批次仿制药一致性评价参比制剂目录，其中新增品种28个、变更及增加持证商品种27个。通知原文经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第七十八批）。涉及品种：硫酸沙丁胺醇吸入粉雾剂、乳酸钠林格冲洗液、盐酸特泊替尼片、盐酸奥洛他定口崩片、注射用丝裂霉素、阿替卡因肾上腺素注射液、达格列净二甲双胍缓释片（Ⅰ）、达格列净二甲双胍缓释片（Ⅰ）、氢溴酸替格列汀片、碘美普尔注射液、碘美普尔注射液、甘油磷酸钠注射液等；仿制药参比制剂目录（第78批）（扫描二维码下载附件）仿制药参比制剂目录（第78批）

100 项与盐酸阿替卡因/重酒石酸肾上腺素相关的药物交易

登录后查看更多信息